Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 9463 participants.

Also called NCT02465515

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 9,463 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02465515
  • EudraCT 2014-001824-32
Other papers using this trial's data
  • Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial Lancet (London, England), 2018-10-27 DOI, PubMed 30291013
  • Effect of albiglutide on cardiovascular outcomes in older adults: A post hoc analysis of a randomized controlled trial Diabetes, obesity & metabolism, 2024-05 DOI, PubMed 38317618

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Belgium, Bulgaria, Canada, Czechia, Denmark, France, Germany, Greece, Hong Kong SAR China, Hungary, Italy, Mexico, Netherlands, Norway, Peru, Philippines, Poland, Russia, South Africa, South Korea, Spain, Sweden, Taiwan, Thailand, Ukraine, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02465515. Randomized; quadruple masking; primary purpose treatment. Start 2015-07-01 (actual); primary completion 2018-02-20 (actual). Results posted on 2019-03-06.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus
Condition
Diabetes Mellitus
Intervention (Biological)
Albiglutide 30 mg
Intervention (Biological)
Albiglutide 50 mg
Intervention (Biological)
Albiglutide matching placebo
Lead sponsor
GlaxoSmithKline (class: industry)
Collaborator
Duke Clinical Research Institute (class: other)

Record details

Record id
cardio:ct-nct02465515
Content hash
f3ecd7fd5fb3cec5ba5873801952129968966b6b55e93fc4ba528dcf0c153a35